Related Experiment Video
Updated: Aug 7, 2026

Adaptation of Microelectrode Array Technology for the Study of Anesthesia-induced Neurotoxicity in the Intact Piglet Brain
Published on: May 12, 2018
Amphetamine neurotoxicity: cause and consequence of oxidative stress
Bryan K Yamamoto1, Michael G Bankson
1Department of Pharmacology, Laboratory of Neurochemistry, Boston University School of Medicine, Boston, MA 02118, USA. bkyam@bu.edu
Abstract:
Oxidative stress has been demonstrated to occur in response to high doses of substituted amphetamines such as methamphetamine (METH) and 3,4-methlyene-dioxymethamphetamine (MDMA). This term represents a set of complex and multi-faceted precursor events that occur in both a parallel and serial manner, eventually converging to produce oxidative damage. This critical review goes beyond the compilation of previously well-documented evidence demonstrating that oxidative stress mediates METH and MDMA toxicity to dopamine and/or serotonin nerve terminals. The diverse causes, effects, and impact of pro-oxidative processes produced by these drugs are highlighted, integrated, and assembled into a proposed temporal sequence in an effort to explain the long-term neurochemical changes produced by amphetamines. Multiple factors are considered, including dopamine, glutamate, impaired mitochondrial bioenergetics, and inflammatory processes, all of which converge and are necessary but alone may be insufficient to cause damage to dopamine and/or 5-HT terminals. In addition, the processes linking inflammation and oxidative stress are considered and described as a feedforward process. The self-perpetuating cycle of inflammation and oxidative stress that is initiated by dopamine, glutamate, and mitochondrial dysfunction may extend well beyond the acute pharmacodynamic effects of the drugs and could represent an underlying and potentially progressive degenerative process.
Related Concept Videos
Drugs Affecting Neurotransmitter Synthesis
Drug Toxicity: Dose-Dependent Reactions
Hepatic Encephalopathy
Drugs Affecting Neurotransmitter Release or Uptake
Parkinson Disease ll: Pathophysiology
Alzheimer Disease l: Introduction

